Top Industry Leaders in the Peptide Anticoagulant Drugs Market
Latest Peptide And Anticoagulant Drugs Companies Updates
Amylin Pharmaceuticals, Inc.: Received FDA approval for Pramlintide (Symlin®), a synthetic peptide analog of amylin, for use in managing Type 1 diabetes in adults in November 2023.
Boehringer Ingelheim: Announced the expansion of its clinical trial program for BI 782571, a novel oral Factor XIa inhibitor as a potential alternative to warfarin, in December 2023.
Roche Holding AG: Received FDA breakthrough therapy designation for RO7380710, a bispecific peptide-drug conjugate targeting IL-17A and IL-17F for treating psoriasis and other inflammatory diseases, in January 2024.
Hsieh's Biopharma Co., Ltd.: Launched a new manufacturing facility in China in February 2024 dedicated to producing peptide drugs, aiming to expand their production capacity and global reach.
PepGen, Inc.: Collaborated with a leading academic institution in January 2024 to develop AI-powered platforms for accelerating peptide drug discovery and optimization.
List of Peptide And Anticoagulant Drugs Key companies in the market:
- Abbott Laboratories (U.S.)
- Cadila Pharmaceuticals (India)
- Sanofi S.A. (France)
- Eli Lilly and Company (U.S.)
- Cipla Limited (India)
- Biocon Limited (India)
- Intas Pharmaceuticals Ltd. (India)
- Lupin Limited (India)
- Emcure Pharmaceuticals Ltd. (India)